OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Coutre Discusses Challenges With CAR T-Cell Therapy in ALL

March 21st 2018

Steven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia.

Dr. Jahanzeb Discusses Advancements in Adjuvant HER2+ Breast Cancer

March 21st 2018

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses advancements in adjuvant HER2-positive breast cancer.

Dr. Donnellan on Combinations Under Investigation in Acute Leukemia

March 21st 2018

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses combinations under investigation in acute leukemia.

Dr. Van Loon on the PROSPECT Trial

March 21st 2018

Katherine Van Loon, MD, gastrointestinal cancer specialist, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the design of the multicenter PROSPECT trial.

Heather Greene on Immune-Related Adverse Events in Patients With NSCLC

March 21st 2018

Heather Greene, a nurse practitioner at West Cancer Center, discusses the most common immune-related adverse events (AEs) in patients with non–small cell lung cancer (NSCLC), and whether or not these AEs vary between agents.

Dr. Lonial Discusses Ongoing Phase III Trials in Multiple Myeloma

March 21st 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses ongoing phase III studies in patients with multiple myeloma.

Dr. Wakelee Discusses EGFR TKIs in Lung Cancer

March 21st 2018

Heather Wakelee, MD, associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses EGFR tyrosine kinase inhibitors (TKIs) in lung cancer.

Dr. Domchek Discusses Immunotherapy in Breast Cancer

March 21st 2018

Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses the development of immunotherapy in breast cancer.

Dr. Overman on the Impact of Nivolumab in mCRC

March 21st 2018

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the impact of nivolumab (Opdivo) on the treatment of patients with metastatic colorectal cancer (mCRC).

Dr. Sacco on Ongoing Trials for Chemoradiation in Head and Neck Cancer

March 21st 2018

Assuntina G. Sacco, MD, assistant professor of medicine, medical oncologist, UC San Diego Health, discusses ongoing trials investigating chemoradiation for patients with head and neck cancer.

Dr. West on Pain Management for Endometrial Cancer

March 21st 2018

Lindsay West, MD, gynecologic oncologist, University of North Carolina (UNC) Department of Obstetrics and Gynecology, UNC School of Medicine, discusses pain management for patients with endometrial cancer.

Dr. Kelley Discusses the Rising Incidence of HCC

March 20th 2018

R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the rising incidence of hepatocellular carcinoma.

Dr. Den Discusses Bone-Targeting Agents in Prostate Cancer

March 20th 2018

Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses bone-targeting agents in prostate cancer.

Dr. Kim Discusses the Impact of the PACIFIC Trial in NSCLC

March 20th 2018

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the impact of the PACIFIC trial in non–small cell lung cancer (NSCLC).

Dr. Flinn on FDA Approval of Frontline Brentuximab Vedotin With AVD in Hodgkin Lymphoma

March 20th 2018

Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of brentuximab vedotin (Adcetris) combined with Adriamycin, vinblastine, and dacarbazine (AVD) as a frontline treatment for patients with advanced classical Hodgkin lymphoma.

Dr. Rao on the SOFT Trial in Patients With Premenopausal Breast Cancer

March 20th 2018

Ruta D. Rao, MD, associate professor, Rush University Medical Center, discusses the results of the SOFT trial, presented at the 2017 San Antonio Breast Cancers Symposium.

Dr. Tempero on Emerging Agents in Pancreatic Cancer

March 20th 2018

Margaret A. Tempero, MD, director, University of California, San Francisco (UCSF) Pancreas Center, professor of medicine, Division of Hematology and Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the interest in the pegylated hyaluronidase agent, PEGPH20, and clinical trials exploring other emerging agents in pancreatic cancer.

Dr. Traina on PARP Inhibition in BRCA-Mutated Breast Cancer

March 19th 2018

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the prevalence of BRCA mutations in triple-negative breast cancer (TNBC).

Dr. Logan Discusses Acalabrutinib in CLL

March 19th 2018

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses acalabrutinib (Calquence) in chronic lymphocytic leukemia.

Dr. Ruan Discusses Biomarkers in MCL

March 19th 2018

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses biomarkers in mantle cell lymphoma.